Free Trial

CytomX Therapeutics (CTMX) Competitors

CytomX Therapeutics logo
$1.00
0.00 (0.00%)
(As of 10/31/2024 ET)

CTMX vs. DRRX, SELB, MEIP, RDHL, KMDA, DSGN, MNPR, INZY, ACIU, and AVIR

Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include DURECT (DRRX), Selecta Biosciences (SELB), MEI Pharma (MEIP), RedHill Biopharma (RDHL), Kamada (KMDA), Design Therapeutics (DSGN), Monopar Therapeutics (MNPR), Inozyme Pharma (INZY), AC Immune (ACIU), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.

CytomX Therapeutics vs.

DURECT (NASDAQ:DRRX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.

DURECT has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

CytomX Therapeutics has a net margin of 9.27% compared to DURECT's net margin of -187.80%. CytomX Therapeutics' return on equity of -27.44% beat DURECT's return on equity.

Company Net Margins Return on Equity Return on Assets
DURECT-187.80% -261.43% -66.98%
CytomX Therapeutics 9.27%-27.44%5.78%

DURECT currently has a consensus target price of $21.00, suggesting a potential upside of 1,490.91%. CytomX Therapeutics has a consensus target price of $5.77, suggesting a potential upside of 479.74%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DURECT
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
CytomX Therapeutics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

28.0% of DURECT shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, DURECT and DURECT both had 1 articles in the media. CytomX Therapeutics' average media sentiment score of 1.45 beat DURECT's score of 0.93 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DURECT
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CytomX Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DURECT$8.41M4.87-$27.62M-$0.95-1.39
CytomX Therapeutics$119.57M0.65-$570K$0.204.98

CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 65.61% of users gave CytomX Therapeutics an outperform vote while only 64.36% of users gave DURECT an outperform vote.

CompanyUnderperformOutperform
DURECTOutperform Votes
316
64.36%
Underperform Votes
175
35.64%
CytomX TherapeuticsOutperform Votes
372
65.61%
Underperform Votes
195
34.39%

Summary

CytomX Therapeutics beats DURECT on 14 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTMX vs. The Competition

MetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$77.58M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio7.1116.06131.9317.57
Price / Sales0.65258.281,440.1578.36
Price / CashN/A50.1639.0633.56
Price / Book-1.405.674.744.57
Net Income-$570,000.00$151.16M$115.43M$225.42M
7 Day Performance-7.81%-1.80%-0.86%-0.61%
1 Month Performance-15.62%5.92%3.61%1.50%
1 Year Performance-9.48%39.97%38.90%32.94%

CytomX Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
4.3778 of 5 stars
$1.00
flat
$5.77
+479.7%
-10.6%$77.58M$119.57M7.11170Upcoming Earnings
News Coverage
Positive News
DRRX
DURECT
3.4071 of 5 stars
$1.48
+3.5%
$21.00
+1,318.9%
-45.8%$45.94M$8.41M-2.4380Positive News
SELB
Selecta Biosciences
N/AN/AN/AN/A$136.76M$110.78M-4.0164Analyst Forecast
Gap Down
High Trading Volume
MEIP
MEI Pharma
4.7529 of 5 stars
$3.09
+13.2%
$7.00
+126.9%
-54.4%$18.19M$65.30M1.16100Analyst Forecast
News Coverage
High Trading Volume
RDHL
RedHill Biopharma
1.2597 of 5 stars
$8.35
+1.8%
N/A-97.3%$10.60M$6.53M0.00210
KMDA
Kamada
4.4466 of 5 stars
$5.45
+3.2%
$14.50
+166.1%
+28.4%$313.27M$154.57M20.19360Short Interest ↓
News Coverage
High Trading Volume
DSGN
Design Therapeutics
2.0664 of 5 stars
$5.53
+1.7%
$7.00
+26.6%
+173.0%$312.42MN/A-6.1440Positive News
MNPR
Monopar Therapeutics
3.872 of 5 stars
$17.83
+5.3%
$22.00
+23.4%
+626.2%$311.74MN/A-7.7510Gap Down
High Trading Volume
INZY
Inozyme Pharma
3.2288 of 5 stars
$4.78
-0.2%
$16.14
+237.7%
+54.9%$299.85MN/A-3.2750Upcoming Earnings
Short Interest ↓
ACIU
AC Immune
3.1306 of 5 stars
$3.00
-1.6%
$12.00
+300.0%
+10.4%$296.70M$15.49M-4.17140Upcoming Earnings
Short Interest ↓
News Coverage
Positive News
AVIR
Atea Pharmaceuticals
3.753 of 5 stars
$3.42
+2.1%
$6.88
+101.2%
+5.8%$288.04M$351.37M-1.6370Short Interest ↓

Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners